FASTBASE obtains a “Cervera Transfer R&D Projects” grant of € 650,000, from the Center for Industrial Technological Development (CDTI) of the Spanish Ministry of Science and Innovation. The funds will go towards the development of QF-Pro (PD-1/PD-L1), a breakthrough assay to predict potential patient´s response to immune oncology treatments, based on our QF-Pro® technology “Quantitative Functional PROteomics platform».
QF-Pro® allows mechanistic detection and quantification of protein-protein and immune checkpoint interactions in the microenvironment of patient biopsies, with an unprecedented resolution of <10nm. This unparalleled precision enables the launch of an assay capable of directly and precisely quantifying the population of PD-1/PD-L1 engaged complexes formed in patient biopsies. Compared to merely observing the level of PD-L1 expression, the formation of these PD-1/PD-L1 complexes is a much more accurate indicator of the pre-disposition of patients to respond to PD-1/PD-inhibitor treatments. L1. The purpose of the development of this trial is to improve the stratification of these immune oncology patients and thus improve the efficacy of these treatments. In Europe alone, there are 3.7 million new cancer patients every year.
This state-of-the-art QF-Pro (PD-1/PD-L1) assay addresses a widely recognized medical need: correctly predicting the potential response of patients to cancer immunotherapy, which is a major challenge in current clinical practice and a strong stressor for patients, doctors and health administrators. Furthermore, it not only better predicts which patients will respond positively, but it is also a tool for pharmaceutical companies to develop even more effective treatments.
The company, which has already validated its technology through clinical trials on more than 150 patients from the Bergonié Institute (France) and the Nottingham University Hospital (UK), aims to launch QF-Pro® (PD-1/PD-L1) in 2023.
Thanks to this financing from the CDTI, and the support of the EiC-SME Instrument of the European Commission and of the institutions of the Basque Country’ ecosystem of Science, Technology and Health, FASTBASE ensures the viability of its QF-Pro® industrialization plan and opens a private fundraising process to finance the regulatory process as a step prior to commercialization in Europe and the United States.
The FASTBASE team also includes among its founders Peter J. Parker, Director of the Division of Cancer Studies (Cancer Research UK) at King’s College London and Director of the Protein area at the Francis Crick Institute (UK), and Antonio Parente, Founder of Lipotec and founder of 5 additional companies in the field of therapeutics and oncology (DiverDrugs, Primaderm, Lipofoods, BCN Peptides and GP Pharm). The spin-off also has the support of HASTEN Ventures, a fund specialized in promotion of deep-tech companies with a high scientific and technological base.